Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 23.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,591 shares of the company’s stock after selling 13,708 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.10% of Y-mAbs Therapeutics worth $586,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in YMAB. Bank of New York Mellon Corp boosted its holdings in shares of Y-mAbs Therapeutics by 8.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after buying an additional 8,974 shares during the period. Rice Hall James & Associates LLC boosted its position in Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock valued at $1,084,000 after purchasing an additional 3,589 shares during the period. Massachusetts Financial Services Co. MA increased its position in Y-mAbs Therapeutics by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock worth $993,000 after buying an additional 2,760 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Y-mAbs Therapeutics in the 2nd quarter valued at about $297,000. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ:YMAB opened at $8.28 on Friday. The firm has a 50 day simple moving average of $12.48 and a 200 day simple moving average of $12.59. Y-mAbs Therapeutics, Inc. has a 52 week low of $6.10 and a 52 week high of $20.90. The company has a market cap of $370.85 million, a PE ratio of -15.33 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same quarter in the prior year, the company earned ($0.18) EPS. On average, equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

YMAB has been the topic of several analyst reports. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Y-mAbs Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $20.89.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.